Although we now know that SMO inhibitors are efficacious in treating a subset of human BCC and MB, it is important to re-examine the initial reports carefully, as these studies established methodological practices that were adopted by the field and are currently employed today. This evidence concerns the gene SMO and skin basal cell carcinoma.